Anergis' AllerT meets in Phase IIb for birch pollen allergy

In September, Anergis S.A. (Epalinges, Switzerland) reported top-line data from the Phase IIb ATIBAR trial in 421 patients with birch pollen allergy showing that 50 μg doses of subcutaneous AllerT met the primary endpoint of improving Combined Symptom and Medication Score (CSMS) vs. placebo. Specifically, AllerT led to a 7% improvement in CSMS (p=0.047), with a 14% reduction in Symptom Score.

On secondary endpoints, AllerT improved mini Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ) scores by 9%, Asthma Symptom and Medication Score by 29% and Nighttime Nasal Symptom Score by 9% vs. placebo (p=0.0526, p<0.0001 and p<0.0001, respectively). The double-blind, European trial evaluated 5 subcutaneous injections of 10 and 50 μg AllerT over a 2-month period...